Akebia Therapeutics, Inc. (AKBA)

Market Cap	782.18M
Revenue (ttm)	203.73M
Net Income (ttm)	-36.48M
Shares Out	265.15M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	52.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,253,912
Open	2.990
Previous Close	2.990
Day's Range	2.910 - 2.990
52-Week Range	1.240 - 4.079
Beta	1.02
Analysts	Strong Buy
Price Target	6.90 (+133.9%)
Earnings Date	Nov 6, 2025

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the t...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Mar 20, 2014
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: AKBA
• Website: https://www.akebia.com

Financial Performance

In 2024, Akebia Therapeutics's revenue was $160.18 million, a decrease of -17.70% compared to the previous year's $194.62 million. Losses were -$69.41 million, 33.7% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for AKBA stock is "Strong Buy." The 12-month stock price target is $6.9, which is an increase of 133.90% from the latest price.

Price Target

$6.9

(133.90% upside)

Analyst Consensus: Strong Buy